{"id":11039,"date":"2026-11-06T00:56:31","date_gmt":"2026-11-05T19:26:31","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/auropharma-share-price-today-2026-11-05\/"},"modified":"2026-11-06T00:56:33","modified_gmt":"2026-11-05T19:26:33","slug":"auropharma-share-price-today-2026-11-05","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/auropharma-share-price-today-2026-11-05\/","title":{"rendered":"Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Rising 4.69% | 5 November 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: AUROPHARMA<\/strong> \u00b7 5 November 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b91,785.00<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>+4.69%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b91,796.80 \/ \u20b91,696.00<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b91,705.00<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>30.99 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>5 November 2026 \u00b7 03:30 PM IST<\/div>\n<\/div>\n<\/div>\n<section class=\"wt-fno-intelligence\" style=\"border:1px solid #d8e1ea;border-radius:14px;padding:15px;margin:20px 0;background:#fff;\">\n<div style=\"font-size:11px;text-transform:uppercase;letter-spacing:.65px;color:#617184;font-weight:900;\">WittyTrades F&amp;O Stock Intelligence<\/div>\n<h2 style=\"margin:3px 0 5px;\">AUROBINDO PHARMA LTD F&amp;O Intelligence<\/h2>\n<p style=\"margin:0 0 12px;font-size:13px;color:#536273;\">Data-mining view of cash participation, delivery, futures activity, open interest and recent positioning.<\/p>\n<div style=\"font-size:11px;text-transform:uppercase;letter-spacing:.6px;color:#697386;font-weight:800;margin:4px 0 7px\">Latest completed-session snapshot<\/div>\n<div style=\"display:grid;grid-template-columns:repeat(auto-fit,minmax(145px,1fr));gap:8px;margin:0 0 15px\">\n<div style=\"border:1px solid #e4e8ef;border-left:4px solid #176c3b;border-radius:11px;padding:10px;background:#f4fbf7;min-width:0\"><span style=\"display:block;font-size:10.5px;color:#687386;font-weight:700\">Cash close<\/span><b style=\"display:block;font-size:17px;line-height:1.25;color:#172033;margin-top:2px\">Rs 1,785.00<\/b><span style=\"display:block;font-size:11px;color:#176c3b;font-weight:800;margin-top:2px\">+4.69%<\/span><\/div>\n<div style=\"border:1px solid #e4e8ef;border-left:4px solid #6b7280;border-radius:11px;padding:10px;background:#fff;min-width:0\"><span style=\"display:block;font-size:10.5px;color:#687386;font-weight:700\">Cash open<\/span><b style=\"display:block;font-size:17px;line-height:1.25;color:#172033;margin-top:2px\">Rs 1,740.10<\/b><\/div>\n<div style=\"border:1px solid #e4e8ef;border-left:4px solid #6b7280;border-radius:11px;padding:10px;background:#fff;min-width:0\"><span style=\"display:block;font-size:10.5px;color:#687386;font-weight:700\">Cash high \/ low<\/span><b style=\"display:block;font-size:17px;line-height:1.25;color:#172033;margin-top:2px\">Rs 1,796.80 \/ Rs 1,696.00<\/b><\/div>\n<div style=\"border:1px solid #e4e8ef;border-left:4px solid #176c3b;border-radius:11px;padding:10px;background:#f4fbf7;min-width:0\"><span style=\"display:block;font-size:10.5px;color:#687386;font-weight:700\">Near future<\/span><b style=\"display:block;font-size:17px;line-height:1.25;color:#172033;margin-top:2px\">Rs 1,779.80<\/b><span style=\"display:block;font-size:11px;color:#176c3b;font-weight:800;margin-top:2px\">+4.05%<\/span><\/div>\n<div style=\"border:1px solid #e4e8ef;border-left:4px solid #8a6414;border-radius:11px;padding:10px;background:#fffaf0;min-width:0\"><span style=\"display:block;font-size:10.5px;color:#687386;font-weight:700\">All-expiry futures OI<\/span><b style=\"display:block;font-size:17px;line-height:1.25;color:#172033;margin-top:2px\">1.43 Cr shares<\/b><span style=\"display:block;font-size:11px;color:#8a6414;font-weight:800;margin-top:2px\">-1.82%<\/span><\/div>\n<div style=\"border:1px solid #e4e8ef;border-left:4px solid #1f5f8f;border-radius:11px;padding:10px;background:#f5faff;min-width:0\"><span style=\"display:block;font-size:10.5px;color:#687386;font-weight:700\">F&amp;O\/Cash participation ratio<\/span><b style=\"display:block;font-size:17px;line-height:1.25;color:#172033;margin-top:2px\">1.65x<\/b><span style=\"display:block;font-size:11px;color:#1f5f8f;font-weight:800;margin-top:2px\">WittyTrades Proprietary<\/span><\/div>\n<\/div>\n<div style=\"border:1px solid #e4c44a;background:linear-gradient(135deg,#fff8d8,#fff3ad);border-radius:13px;padding:13px;margin:12px 0 16px;\">\n<div style=\"font-size:11px;font-weight:900;letter-spacing:.55px;text-transform:uppercase;color:#725a00;margin-bottom:8px;\">WittyTrades Proprietary Metrics<\/div>\n<div style=\"display:grid;grid-template-columns:repeat(auto-fit,minmax(210px,1fr));gap:9px;\">\n<div style=\"background:#fff;border:1px solid #ead989;border-radius:10px;padding:10px;\"><span style=\"display:block;font-size:11px;color:#6c6250;font-weight:700;\">Shares Traded per Trade<\/span><b style=\"display:block;font-size:22px;color:#172033;margin-top:2px;\">28.2<\/b><small style=\"display:block;font-size:11px;color:#6f6654;line-height:1.45;margin-top:4px;\">3-session average: 25.6. Formula: cash shares traded \u00f7 number of trades.<\/small><\/div>\n<div style=\"background:#fff;border:1px solid #b9d8f4;border-radius:10px;padding:10px;\"><span style=\"display:block;font-size:11px;color:#496a88;font-weight:700;\">F&amp;O\/Cash Participation Ratio<\/span><b style=\"display:block;font-size:22px;color:#1f5f8f;margin-top:2px;\">1.65x<\/b><small style=\"display:block;font-size:11px;color:#58758f;line-height:1.45;margin-top:4px;\">Formula: futures-equivalent shares \u00f7 cash shares. 3-session trend: 0.99x \u2192 1.35x \u2192 1.65x.<\/small><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<div style=\"font-size:11px;text-transform:uppercase;letter-spacing:.6px;color:#697386;font-weight:800;\">NSE cash-market participation<\/div>\n<h3 style=\"font-size:18px;margin:3px 0 9px;color:#17324d;\">Last 3 Sessions: Cash Activity &amp; Delivery<\/h3>\n<div style=\"overflow-x:auto;-webkit-overflow-scrolling:touch;border:1px solid #e5eaf0;border-radius:11px;\">\n<table style=\"border-collapse:collapse;width:100%;min-width:820px;margin:0;\">\n<thead>\n<tr>\n<th style=\"background:#f6f8fb;white-space:nowrap;padding:8px 9px;text-align:left;border-bottom:1px solid #e4e8ef;font-size:11px;color:#5d6878;text-transform:uppercase;\">Date<\/th>\n<th style=\"background:#f6f8fb;white-space:nowrap;padding:8px 9px;text-align:left;border-bottom:1px solid #e4e8ef;font-size:11px;color:#5d6878;text-transform:uppercase;\">Cash Volume<\/th>\n<th style=\"background:#f6f8fb;white-space:nowrap;padding:8px 9px;text-align:left;border-bottom:1px solid #e4e8ef;font-size:11px;color:#5d6878;text-transform:uppercase;\">Number of Trades<\/th>\n<th style=\"background:#fff2bf;white-space:nowrap;padding:8px 9px;text-align:left;border-bottom:1px solid #e4e8ef;font-size:11px;color:#5d6878;text-transform:uppercase;\">Shares Traded per Trade<\/th>\n<th style=\"background:#f6f8fb;white-space:nowrap;padding:8px 9px;text-align:left;border-bottom:1px solid #e4e8ef;font-size:11px;color:#5d6878;text-transform:uppercase;\">Delivery %<\/th>\n<th style=\"background:#f6f8fb;white-space:nowrap;padding:8px 9px;text-align:left;border-bottom:1px solid #e4e8ef;font-size:11px;color:#5d6878;text-transform:uppercase;\">Close \/ Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong>03 Nov<\/strong><\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\">13.23 L shares<\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\">58,020<\/td>\n<td style=\"background:#fff8db;white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong>22.8<\/strong><br \/><span style=\"font-size:9.5px;font-weight:900;color:#725a00;\">WittyTrades Proprietary<\/span><\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\">59.64%<\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong>Rs 1,694.50<\/strong> <span style=\"color:#176c3b;font-weight:800\">(+0.64%)<\/span><\/td>\n<\/tr>\n<tr>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong>04 Nov<\/strong><\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\">21.39 L shares<\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\">83,445<\/td>\n<td style=\"background:#fff8db;white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong>25.6<\/strong><br \/><span style=\"font-size:9.5px;font-weight:900;color:#725a00;\">WittyTrades Proprietary<\/span><\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\">62.65%<\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong>Rs 1,705.00<\/strong> <span style=\"color:#176c3b;font-weight:800\">(+0.62%)<\/span><\/td>\n<\/tr>\n<tr>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong>05 Nov<\/strong><\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\">30.99 L shares<\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\">109,754<\/td>\n<td style=\"background:#fff8db;white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong>28.2<\/strong><br \/><span style=\"font-size:9.5px;font-weight:900;color:#725a00;\">WittyTrades Proprietary<\/span><\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\">34.68%<\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong>Rs 1,785.00<\/strong> <span style=\"color:#176c3b;font-weight:800\">(+4.69%)<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div style=\"background:#fff8d9;border-left:4px solid #e3b600;padding:11px 12px;border-radius:8px;margin:11px 0;font-size:13px;\"><strong>WittyTrades Proprietary Metric: Large-Ticket Activity Proxy<\/strong><br \/>Average number of shares traded per trade was <strong>28.2<\/strong> in the latest session versus a <strong>25.6<\/strong> 3-session average. The latest average trade size was close to its 3-session baseline rather than showing a clear larger-ticket surge. Latest delivery was 34.7% versus a 3-session average of 52.3%.<\/div>\n<div style=\"font-size:11px;text-transform:uppercase;letter-spacing:.6px;color:#697386;font-weight:800;margin-top:17px;\">Futures participation<\/div>\n<h3 style=\"font-size:18px;margin:3px 0 9px;color:#17324d;\">Last 3 Sessions: Futures vs Cash Participation<\/h3>\n<div style=\"overflow-x:auto;-webkit-overflow-scrolling:touch;border:1px solid #e5eaf0;border-radius:11px;\">\n<table style=\"border-collapse:collapse;width:100%;min-width:1040px;margin:0;\">\n<thead>\n<tr>\n<th style=\"background:#f6f8fb;white-space:nowrap;padding:8px 9px;text-align:left;border-bottom:1px solid #e4e8ef;font-size:11px;color:#5d6878;text-transform:uppercase;\">Date<\/th>\n<th style=\"background:#f6f8fb;white-space:nowrap;padding:8px 9px;text-align:left;border-bottom:1px solid #e4e8ef;font-size:11px;color:#5d6878;text-transform:uppercase;\">Near Future \/ Change<\/th>\n<th style=\"background:#f6f8fb;white-space:nowrap;padding:8px 9px;text-align:left;border-bottom:1px solid #e4e8ef;font-size:11px;color:#5d6878;text-transform:uppercase;\">Futures Volume (Shares)<\/th>\n<th style=\"background:#f6f8fb;white-space:nowrap;padding:8px 9px;text-align:left;border-bottom:1px solid #e4e8ef;font-size:11px;color:#5d6878;text-transform:uppercase;\">Cash Volume (Shares)<\/th>\n<th style=\"background:#fff2bf;white-space:nowrap;padding:8px 9px;text-align:left;border-bottom:1px solid #e4e8ef;font-size:11px;color:#5d6878;text-transform:uppercase;\">F&amp;O\/Cash Participation Ratio<\/th>\n<th style=\"background:#f6f8fb;white-space:nowrap;padding:8px 9px;text-align:left;border-bottom:1px solid #e4e8ef;font-size:11px;color:#5d6878;text-transform:uppercase;\">Aggregate Futures OI<\/th>\n<th style=\"background:#f6f8fb;white-space:nowrap;padding:8px 9px;text-align:left;border-bottom:1px solid #e4e8ef;font-size:11px;color:#5d6878;text-transform:uppercase;\">Positioning Read<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong>03 Nov<\/strong><\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong>Rs 1,691.50<\/strong> <span style=\"color:#176c3b;font-weight:800\">(+0.71%)<\/span><\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\">13.14 L shares<\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\">13.23 L shares<\/td>\n<td style=\"background:#fff8db;white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong style=\"color:#1f5f8f\">0.99x<\/strong><br \/><span style=\"font-size:9.5px;font-weight:900;color:#1f5f8f;\">WittyTrades Proprietary<\/span><\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\">1.42 Cr shares <span style=\"color:#b23434;font-weight:800\">(\u2014)<\/span><\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong>Positioning unavailable<\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong>04 Nov<\/strong><\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong>Rs 1,710.50<\/strong> <span style=\"color:#176c3b;font-weight:800\">(+1.12%)<\/span><\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\">28.87 L shares<\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\">21.39 L shares<\/td>\n<td style=\"background:#fff8db;white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong style=\"color:#1f5f8f\">1.35x<\/strong><br \/><span style=\"font-size:9.5px;font-weight:900;color:#1f5f8f;\">WittyTrades Proprietary<\/span><\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\">1.46 Cr shares <span style=\"color:#176c3b;font-weight:800\">(+2.64%)<\/span><\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong>Long buildup<\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong>05 Nov<\/strong><\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong>Rs 1,779.80<\/strong> <span style=\"color:#176c3b;font-weight:800\">(+4.05%)<\/span><\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\">51.27 L shares<\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\">30.99 L shares<\/td>\n<td style=\"background:#fff8db;white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong style=\"color:#1f5f8f\">1.65x<\/strong><br \/><span style=\"font-size:9.5px;font-weight:900;color:#1f5f8f;\">WittyTrades Proprietary<\/span><\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\">1.43 Cr shares <span style=\"color:#b23434;font-weight:800\">(-1.82%)<\/span><\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong>Short covering<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div style=\"background:#eef6ff;border-left:4px solid #2e7db2;padding:11px 12px;border-radius:8px;margin:11px 0;font-size:13px;\"><strong>Participation read:<\/strong> Futures-equivalent volume was 1.65 times cash-market share volume in the latest completed session. The latest price\/OI classification is <strong>Short covering<\/strong>. Classification uses aggregate all-expiry OI to reduce front-month rollover distortion.<\/div>\n<div style=\"margin-top:18px\">\n<div style=\"font-size:11px;text-transform:uppercase;letter-spacing:.6px;color:#697386;font-weight:800;\">Expiry &amp; contract migration<\/div>\n<h3 style=\"font-size:18px;margin:3px 0 9px;color:#17324d;\">How open interest shifted across expiries<\/h3>\n<div style=\"overflow-x:auto;-webkit-overflow-scrolling:touch;border:1px solid #e5eaf0;border-radius:11px;\">\n<table style=\"border-collapse:collapse;width:100%;min-width:520px;margin:0;\">\n<thead>\n<tr>\n<th style=\"background:#f6f8fb;white-space:nowrap;padding:8px 9px;text-align:left;border-bottom:1px solid #e4e8ef;font-size:11px;color:#5d6878;text-transform:uppercase;\">Expiry<\/th>\n<th style=\"background:#f6f8fb;white-space:nowrap;padding:8px 9px;text-align:left;border-bottom:1px solid #e4e8ef;font-size:11px;color:#5d6878;text-transform:uppercase;\">Latest OI<\/th>\n<th style=\"background:#f6f8fb;white-space:nowrap;padding:8px 9px;text-align:left;border-bottom:1px solid #e4e8ef;font-size:11px;color:#5d6878;text-transform:uppercase;\">1-Day OI Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong>23 Nov<\/strong><\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\">1.41 Cr shares<\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong>-3.01 L<\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong>29 Dec<\/strong><\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\">1.64 L shares<\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong>+27,500<\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong>25 Jan<\/strong><\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\">20,350 shares<\/td>\n<td style=\"white-space:nowrap;padding:8px 9px;border-bottom:1px solid #edf0f4;font-size:13px;vertical-align:top;\"><strong>+9,350<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"font-size:13px;color:#536273;margin:9px 0 0;\">The front expiry lost OI while later expiries gained OI, confirming contract migration. About 1.3% of aggregate OI sat beyond the front expiry. This is an expiry-structure observation, not a directional signal by itself.<\/p>\n<\/div>\n<div style=\"margin-top:17px;background:#f7fbff;border-left:4px solid #2e7db2;border-radius:9px;padding:12px 13px;\">\n        <strong>What to monitor next<\/strong><\/p>\n<ul style=\"margin:7px 0 0;padding-left:19px;font-size:13px;line-height:1.55;\">\n<li>Whether aggregate futures OI expands or contracts alongside the next price move.<\/li>\n<li>Whether the WittyTrades F&amp;O\/Cash Participation Ratio remains elevated or normalises.<\/li>\n<li>Whether Shares Traded per Trade moves materially above or below its recent baseline.<\/li>\n<li>Whether delivery participation holds above or below the recent 3-session average of 52.3%.<\/li>\n<li>Whether later-expiry OI continues to absorb positions from the front contract as expiry approaches.<\/li>\n<\/ul><\/div>\n<p style=\"margin:10px 0 0;font-size:11px;color:#687386;\">Higher Shares Traded per Trade can flag larger-ticket participation, but exchange trade-count data does not identify the buyer or seller category. The F&amp;O\/Cash Participation Ratio measures participation intensity and does not by itself distinguish directional trading, hedging or arbitrage.<\/p>\n<\/section>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Aurobindo Pharma Limited shares advanced 4.69% on November 5, 2026, closing at \u20b91,785.00 after moving between an intraday low of \u20b91,696.00 and a high of \u20b91,796.00, which also marked a new 52-week high.<\/li>\n<li>Aurobindo Pharma reported its financial results for the quarter ended September 30, 2026, posting a record quarterly revenue of \u20b910,263 crore and a net profit of \u20b91,124 crore, alongside an EBITDA of \u20b92,156 crore. The Board also declared an interim dividend of \u20b97.00 per equity share of Re. 1, fixing November 11, 2026, as the record date.<\/li>\n<li>Trading volume was 3.51 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is Aurobindo Pharma share price rising on 5 November 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Aurobindo Pharma Limited shares advanced 4.69% on November 5, 2026, closing at \u20b91,785.00 after moving between an intraday low of \u20b91,696.00 and a high of \u20b91,796.00, which also marked a new 52-week high.<\/p>\n<p class=\"wt-copy\">The broader market and sector also experienced positive momentum during the session, with the Nifty benchmark gaining 2.40% and the Nifty Pharma sector index rising 1.00%. Aurobindo Pharma outperformed both benchmarks, building on a strong recent trajectory that includes a 5-day return of 7.54% and a 20-day return of 6.12%.<\/p>\n<p class=\"wt-copy\">Company filings from November 4, 2026 outline multiple material corporate updates, including record second-quarter financial results for FY27 with revenue touching \u20b910,263 crore and a net profit of \u20b91,124 crore, alongside an interim dividend of \u20b97.00 per share with a record date of November 11, 2026. Additional announcements covered internal restructuring, such as the proposed merger of Auroactive Pharma Private Limited into Apitoria Pharma Private Limited and the transfer of ownership of Auro Pharma LLC in Russia.<\/p>\n<p class=\"wt-copy\">30.99 lakh shares traded by 5 November 2026 \u00b7 03:30 PM IST. This compares with a 20-day average daily volume of 8.83 lakh shares (3.51 times). The five-day average daily volume was 11.13 lakh shares. Separately, the NSE report for 5 November 2026 showed 10.75 lakh shares delivered, representing 34.68% of that day\u2019s traded volume. The same report recorded 109,754 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>Post-earnings momentum and strong volume participation<\/strong><\/p>\n<p class=\"wt-copy\">The stock&#x27;s 4.69% advance and heavy volume\u20143.51 times its 20-day average\u2014coincided closely with the release of record Q2 FY27 financial results, strong profitability metrics, and a \u20b97.00 interim dividend announcement.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\"><span style=\"display:block;font-size:11px;font-weight:900;letter-spacing:.5px;text-transform:uppercase;margin-bottom:3px;\">WittyTrades.com<\/span>Beyond Charts \u2014 Research Backed by Data.<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Strong Q2 FY27 Financial Results and Dividend Declaration<\/div>\n<div class=\"wt-card-date\">4 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Aurobindo Pharma reported its financial results for the quarter ended September 30, 2026, posting a record quarterly revenue of \u20b910,263 crore and a net profit of \u20b91,124 crore, alongside an EBITDA of \u20b92,156 crore. The Board also declared an interim dividend of \u20b97.00 per equity share of Re. 1, fixing November 11, 2026, as the record date.<\/p>\n<p class=\"wt-copy\">Demonstrates robust operational performance and strong cash generation across key international markets, directly impacting investor valuation.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Proposed Merger of Wholly Owned Subsidiaries<\/div>\n<div class=\"wt-card-date\">4 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The Board of Directors approved a scheme of amalgamation for the merger of Auroactive Pharma Private Limited with Apitoria Pharma Private Limited, both wholly owned subsidiaries engaged in active pharmaceutical ingredients. The transaction aims to consolidate API businesses, improve operational efficiencies, and streamline the group&#x27;s corporate structure.<\/p>\n<p class=\"wt-copy\">Enhances internal operational efficiency and capacity utilization within the group&#x27;s manufacturing framework.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Ownership Transfer of Russian Step-Down Subsidiary<\/div>\n<div class=\"wt-card-date\">4 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The company approved the transfer of ownership of Auro Pharma LLC, Russia, from Auro Active Pharma Private Limited to Auropharm Overseas Limited for a cash consideration of approximately \u20b929 crore. Both entities are wholly owned subsidiaries of Aurobindo Pharma.<\/p>\n<p class=\"wt-copy\">Represents an internal corporate reorganization to streamline holdings of the Russian subsidiary.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Aurobindo Pharma Q2 Results: Profit Rises 33%, Shareholders To Get Dividend By Nov 20 &#8211; NDTV Profit<\/div>\n<div class=\"wt-card-date\">4 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Aurobindo Pharma Q2 Results: Profit Rises 33%, Shareholders To Get Dividend By Nov 20 NDTV Profit<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Aurobindo Pharma Q2: Net profit rises 32.5% to Rs 1,124 crore, revenue hits record high &#8211; Moneycontrol.com<\/div>\n<div class=\"wt-card-date\">4 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Aurobindo Pharma Q2: Net profit rises 32.5% to Rs 1,124 crore, revenue hits record high Moneycontrol.com<\/p>\n<\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">51.88%<\/div>\n<div class=\"wt-note\">51.88% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">17.41%<\/div>\n<div class=\"wt-note\">16.38% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">41.83%<\/div>\n<div class=\"wt-note\">41.48% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1737425_14102026114826_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 16.31% on 30 September 2026. This compares with 16.71% on 30 June 2026, a change of -0.40 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 44 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">QUANT MUTUAL FUND &#8211; QUANT ARBITRAGE FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">2.83 crore shares \u00b7 4.91%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">SBI NIFTY MIDCAP 150 INDEX FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">2.02 crore shares \u00b7 3.51%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">HDFC MUTUAL FUND-HDFC ARBITRAGE FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">1.85 crore shares \u00b7 3.22%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1737425_14102026114826_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>Research &amp; Brokerage Views<\/h2>\n<div class=\"wt-grid wt-grid-brokerage\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Nuvama<\/div>\n<div class=\"wt-card-date\">23 June 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-broker-facts\"><span><span class=\"wt-label\">Rating<\/span><strong>Buy<\/strong><\/span><\/div>\n<p class=\"wt-copy\">Maintained a positive stance on Aurobindo Pharma supported by solid operational growth and expanding market share.<\/p>\n<div class=\"wt-note wt-source-note\">Attributed brokerage opinion; not a WittyTrades recommendation.<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Execution of the proposed merger between Auroactive Pharma and Apitoria Pharma through the NCLT process.<\/li>\n<li>Developments regarding the record date of November 11, 2026 for the interim dividend payout.<\/li>\n<li>Sustained volume participation relative to the 20-day average volume of 3.51x.<\/li>\n<li>Integration progress and performance of recent US market product launches and acquisitions.<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/auropharma-share-price-today-2026-10-23\/\">Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Falling 2.43% | 23 October 2026 \u2014 23 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/auropharma-share-price-today-2026-10-22\/\">Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Rising 1.41% | 22 October 2026 \u2014 22 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/auropharma-share-price-today-2026-10-19\/\">Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Falling 3.08% | 19 October 2026 \u2014 19 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/auropharma\/\">More Aurobindo Pharma news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Aurobindo Pharma company news?<\/h3>\n<p class=\"wt-copy\">Aurobindo Pharma reported its financial results for the quarter ended September 30, 2026, posting a record quarterly revenue of \u20b910,263 crore and a net profit of \u20b91,124 crore, alongside an EBITDA of \u20b92,156 crore. The Board also declared an interim dividend of \u20b97.00 per equity share of Re. 1, fixing November 11, 2026, as the record date.<\/p>\n<h3>How strong was Aurobindo Pharma\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">30.99 lakh shares traded, 3.51 times the 20-day average daily volume. The price and volume data are dated 5 November 2026 \u00b7 03:30 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><br \/><strong>SEBI Registration No.:<\/strong> INH000008172 \u00b7 <strong>BSE Enlistment No.:<\/strong> 5430<\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@type\": \"WebSite\", \"@id\": \"https:\/\/www.wittytrades.com\/#website\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"name\": \"WittyTrades\", \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"inLanguage\": \"en-IN\"}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#organization\", \"name\": \"WittyTrades\", \"alternateName\": \"Witty Networks\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"telephone\": \"+91-22-48972020\", \"identifier\": [{\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}, {\"@type\": \"PropertyValue\", \"propertyID\": \"BSE Research Analyst Code\", \"value\": \"5430\"}]}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"parentOrganization\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}}, {\"@type\": \"Person\", \"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"worksFor\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}}, {\"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/auropharma-share-price-today-2026-11-05\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/auropharma-share-price-today-2026-11-05\/\"}, \"headline\": \"Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Rising 4.69% | 5 November 2026\", \"description\": \"Aurobindo Pharma share price rose 4.69% to \u20b91,785.00 today. See why AUROPHARMA is rising, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-11-06T00:56:21.900908+05:30\", \"dateModified\": \"2026-11-06T00:56:21.900908+05:30\", \"author\": {\"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\"}, \"reviewedBy\": {\"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\"}, \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"isPartOf\": {\"@id\": \"https:\/\/www.wittytrades.com\/#website\"}, \"about\": {\"@type\": \"Thing\", \"name\": \"Aurobindo Pharma\", \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"NSE Symbol\", \"value\": \"AUROPHARMA\"}}, \"inLanguage\": \"en-IN\", \"isAccessibleForFree\": true, \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/11\/auropharma-company-news-2026-11-05.jpg\"]}]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Aurobindo Pharma Q2 Results: Profit Rises 33%, Shareholders To Get Dividend By Nov 20 - NDTV Profit\",\"summary\":\"Aurobindo Pharma Q2 Results: Profit Rises 33%, Shareholders To Get Dividend By Nov 20 NDTV Profit\",\"source\":\"NDTV Profit\",\"published\":\"Wed, 04 Nov 2026 15:10:35 GMT\",\"source_type\":\"business media\",\"generic_watchlist\":false},{\"title\":\"Aurobindo Pharma Q2: Net profit rises 32.5% to Rs 1,124 crore, revenue hits record high - Moneycontrol.com\",\"summary\":\"Aurobindo Pharma Q2: Net profit rises 32.5% to Rs 1,124 crore, revenue hits record high Moneycontrol.com\",\"source\":\"Moneycontrol.com\",\"published\":\"Wed, 04 Nov 2026 16:19:00 GMT\",\"source_type\":\"business media\",\"generic_watchlist\":false},{\"title\":\"Aurobindo Pharma reports 32.5% jump in Q2 net profit to \u20b91,124 crore on record revenue from operations - The Times of India\",\"summary\":\"Aurobindo Pharma reports 32.5% jump in Q2 net profit to \u20b91,124 crore on record revenue from operations The Times of India\",\"source\":\"The Times of India\",\"published\":\"Wed, 04 Nov 2026 15:07:00 GMT\",\"source_type\":\"business media\",\"generic_watchlist\":false}],\"recent_news\":[{\"summary\":\"a press release dated November 04, 2026, titled \\\"Press release on Q2 FY27 Financial Results.\\\".\",\"category\":\"Press Release\",\"date\":\"04-Nov-2026 20:09:09\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/AUROPHARMA_04112026200852_LtrToSEsPressRelease04112026.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"04-Nov-2026 19:53:46\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/AUROPHARMA_04112026194825_LtrToSEsOutcomeOfBM04112026.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"transfer ownership of Auro Pharma LLC, Russia, from Auro Active Pharma Private Limited to Auropharm Overseas Limited, wholly owned subsidiaries of the Company.\",\"category\":\"Acquisition\",\"date\":\"04-Nov-2026 20:31:29\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/AUROPHARMA_04112026203119_LtrToSEsOwnershipTransferRussia04112026.pdf\",\"headline\":\"Investment \/ acquisition update\",\"impact\":\"The transaction can affect growth strategy, capital allocation or market access. Investors should consider the size of the investment, ownership acquired and expected returns.\",\"importance_score\":4,\"completeness_score\":5},{\"summary\":\"a press release dated October 03, 2026, titled \\\"Aurobindo Pharma receives USFDA Final Approval for Perampanel Tablets, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg\\\".\",\"category\":\"Press Release\",\"date\":\"03-Oct-2026 17:03:34\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/AUROPHARMA_03102026170252_LtrToSEsPressReleasePerampanelUSFDAapproval03102026.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3}],\"promoter_pledge\":{\"summary\":\"The promoter\/promoter-group disclosure states that the shares covered by the filing were free from encumbrance.\",\"events\":[{\"summary\":\"UMBAI-400 051 Company Code No. AUROPHARMA Dear Sir I Madam, To The Corporate Relations Department SSE LIMITED Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI-400 001 Company Code No. 524804 Sub: Disclosure of encumbrance pursuant to Reg. 31(4) SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Pursuant to the applicable provisions of Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, I, K. Nithyananda Reddy, one of the Promoters of the Company and on behalf of the other promoter and Promoter Group of the Company hereby declare that we have not made any encumbrance, directlyor indirectly, on the shares held by us in Aurobindo Pharma Limited, other than those already disclosed to the Stock Exchanges during the financial year ended on March 31,2026. I am enclosing herewith the list of promoters and promoter group of Aurobindo Pharma Limited without PAN as on March 31, 2026 Please take the information on record . Thanking you, Yours faithfully, \\\\L. __ - II K. NITHYANANDA REDDY AUTHORISED SIGNATORY (PROMOTRS & PROMOTER GROUP-AUROBINDO PHARMA LIMITED) Plot No 75 and 76, Huda EncLave B, Nandagiri Hills Jubilee Hi\",\"category\":\"Disclosure under SEBI Takeover Regulations\",\"date\":\"19-Jun-2026 16:03:17\",\"source\":\"NSE corporate filing\",\"attachment\":\"https:\/\/nsearchives.nseindia.com\/corporate\/team_bbodade_11052026184659_AUROPHARMA.pdf\",\"detail_level\":\"pdf_facts\"}],\"source\":\"NSE corporate filing\"},\"shareholding_snapshot\":{\"promoter_pct\":51.88,\"public_pct\":48.12,\"fii_pct\":17.41,\"dii_pct\":24.42,\"mf_pct\":16.31,\"institutional_pct\":41.83,\"noninst_pct\":6.29,\"mf_scheme_count\":44,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"QUANT MUTUAL FUND - QUANT ARBITRAGE FUND\",\"shares\":28265663,\"pct\":4.91},{\"name\":\"SBI NIFTY MIDCAP 150 INDEX FUND\",\"shares\":20175334,\"pct\":3.51},{\"name\":\"HDFC MUTUAL FUND-HDFC ARBITRAGE FUND\",\"shares\":18548115,\"pct\":3.22}],\"period\":\"30-SEP-2026\",\"submission_date\":\"14-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1737425_14102026114826_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":51.88,\"previous_fii_pct\":16.38,\"previous_dii_pct\":25.1,\"previous_mf_pct\":16.71,\"previous_institutional_pct\":41.48,\"previous_mf_scheme_count\":42,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"brokerage_views\":[{\"brokerage\":\"Nuvama\",\"rating\":\"Buy\",\"target\":null,\"view_summary\":\"Aurobindo Pharma shares up 25% in 2026: Nuvama says 'Buy', ups target price; here's why Business Today\",\"headline\":\"Aurobindo Pharma shares up 25% in 2026: Nuvama says 'Buy', ups target price; here's why\",\"published\":\"2026-06-23T07:00:00+00:00\",\"source\":\"Business Today\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aurobindo Pharma share price rose 4.69% to \u20b91,785.00 today. See why AUROPHARMA is rising, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":11038,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Rising 4.69% | 5 November 2026","_witty_meta_description":"Aurobindo Pharma share price rose 4.69% to \u20b91,785.00 today. See why AUROPHARMA is rising, volume context, company developments and what to watch next.","_witty_primary_phrase":"Aurobindo Pharma share price today","_witty_reason_label":"Post-earnings momentum and strong volume participation","_witty_reason_confidence":"medium","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[89],"class_list":["post-11039","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-auropharma"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/11039","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=11039"}],"version-history":[{"count":1,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/11039\/revisions"}],"predecessor-version":[{"id":11040,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/11039\/revisions\/11040"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/11038"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=11039"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=11039"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=11039"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}